Reentrant Wavelength and Excitable Gap

Reentrant Wavelength and Excitable Gap are fundamental electrophysiological concepts describing the spatial and temporal properties of reentrant cardiac arrhythmias. They determine the conditions necessary for reentry circuits to initiate and sustain abnormal cardiac rhythms.

Reentrant Wavelength

The Reentrant Wavelength is defined as the minimum spatial length of cardiac tissue required for a reentrant circuit to perpetuate itself. It represents the product of the conduction velocity (CV) of the cardiac action potential and the effective refractory period (ERP) of the tissue. The ERP is the minimum time interval during which cardiac cells cannot be re-excited after an action potential.

Mathematically, the Reentrant Wavelength (λ) can be expressed as:

Where:

• λ is the reentrant wavelength (in millimeters or centimeters),
• CV is the conduction velocity (in millimeters or centimeters per millisecond),
• ERP is the effective refractory period (in milliseconds).

The significance of the reentrant wavelength lies in its role as a spatial threshold; a reentrant circuit can only be maintained if the available pathway length is equal to or longer than the wavelength. If the pathway is shorter than the wavelength, the circulating impulse encounters refractory tissue, preventing continuous propagation and reentry.

Factors that influence the reentrant wavelength include:

• Changes in conduction velocity: Slower conduction velocity reduces the wavelength, facilitating reentry.
• Alterations in refractory period: Shortening of the ERP reduces the wavelength, making reentry more likely.

Therefore, pathophysiological conditions that decrease conduction velocity or ERP favor the development of reentrant arrhythmias.

Excitable Gap

The Excitable Gap refers to the portion of the reentrant circuit where cardiac tissue has recovered excitability before the arrival of the reentrant wavefront. It is the time interval or spatial segment within the circuit during which cells are capable of being depolarized again, despite the ongoing reentrant activity.

This gap is essential for the perpetuation of reentry because it allows the circulating impulse to propagate continuously without encountering refractory tissue.

Characteristics of the Excitable Gap

• It represents the time between the end of the refractory period of the tissue and the arrival of the next impulse.
• The size of the excitable gap depends on the relationship between conduction velocity, refractory period, and the length of the reentrant pathway.
• A wide excitable gap implies a larger window of excitable tissue ahead of the wavefront, which promotes stable and sustained reentry.
• A narrow or absent excitable gap can lead to termination of reentry due to collision of the impulse with refractory tissue.

Quantitative Description

If the total cycle length (CL) of the reentrant circuit is the time for one complete revolution of the impulse around the circuit, then:

Where:

• CL is the cycle length,
• ERP is the effective refractory period.

A positive excitable gap indicates that there is tissue recovered and excitable ahead of the circulating wavefront.

Relationship Between Reentrant Wavelength and Excitable Gap

The reentrant wavelength and excitable gap are interrelated properties that determine the stability and sustainability of reentrant arrhythmias.

• The wavelength defines the minimum pathway length necessary for reentry.
• The excitable gap represents the temporal and spatial availability of tissue that can be excited ahead of the reentrant wave.

If the pathway length is fixed, alterations in conduction velocity and refractory period change both wavelength and excitable gap:

• A short wavelength relative to the circuit length increases the excitable gap, promoting stable reentry.
• A wavelength approaching or exceeding the pathway length reduces or eliminates the excitable gap, causing termination of reentry.

This interplay explains why drugs or conditions that prolong refractory periods or increase conduction velocity can suppress reentrant arrhythmias by increasing the wavelength and reducing the excitable gap.

Clinical and Experimental Implications

Understanding reentrant wavelength and excitable gap is critical in the diagnosis and treatment of cardiac arrhythmias:

• Antiarrhythmic drugs often act by prolonging ERP or slowing conduction, thus increasing wavelength and reducing the likelihood of reentry.
• Ablation therapy targets critical areas of the reentry circuit to disrupt the pathway length, making it shorter than the wavelength.
• Electrophysiological studies measure cycle length, conduction velocity, and refractory periods to infer the presence and properties of reentrant circuits.

Summary Table of Key Concepts

This comprehensive understanding of reentrant wavelength and excitable gap serves as the foundation for analyzing mechanisms of arrhythmogenesis and guiding therapeutic strategies in cardiac electrophysiology.